Cogent Biosciences, Inc. (NASDAQ:COGT) is one of Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.
Cogent Biosciences, Inc. (NASDAQ:COGT) is a relatively recent addition to the 13F portfolio of Duquesne Capital. The fund first disclosed a stake in the company in the third quarter of 2025. This position comprised just over a million shares. Filings for the fourth quarter of 2025 show that the fund has more than doubled this holding, upping it to more than 2.2 million shares. Cogent is a clinical-stage biotechnology firm focused on developing precision therapies for genetically defined diseases. A lead product candidate for the firm includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase.
Hedge funds are betting on a valuation re-rating of Cogent Biosciences, Inc. (NASDAQ:COGT) stock in light of three critical regulatory milestones that the company has achieved. On March 16, 2026, the FDA officially accepted the New Drug Application (NDA) for bezuclastinib based on the pivotal SUMMIT trial. On April 1, Cogent submitted a second NDA for GIST under the FDA’s Real-Time Oncology Review (RTOR) program, which significantly accelerates the approval timeline. The FDA granted this status in late January 2026, signaling that bezuclastinib is viewed as a potentially superior treatment to current standards of care. Institutional investors are focused on the deepening clinical benefit revealed in the 48-week data from the SUMMIT trial, released Feb 2026. Patients saw a 56% relative improvement in symptoms, with 86% of patients hitting clinically meaningful benchmarks.
While we acknowledge the potential of COGT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Stocks to Buy According to Billionaire David Abrams and 15 Best Stocks to Buy According to Billionaire Seth Klarman.
Disclosure: None. Follow Insider Monkey on Google News.
